HealthQuill Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals, Inc. plans to buy most of the assets of the bankrupt genetics and biotechnology company, 23andMe Holding, for $256 million.
Drugs Medical Pharma

Regeneron to buy bankrupt 23andMe Holding assets for $256 million

HQ Team May 20, 2025: Regeneron Pharmaceuticals, Inc. plans to buy most of the assets of the bankrupt genetics and biotechnology company, 23andMe.

Read More